These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19756636)

  • 1. [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application].
    Kernt M; Hirneiss C; Neubauer AS; Liegl RG; Eibl KH; Wolf A; de Kaspar H; Ulbig MW; Kampik A
    Ophthalmologe; 2010 Aug; 107(8):720-7. PubMed ID: 19756636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracameral moxifloxacin: in vitro safety on human ocular cells.
    Kernt M; Neubauer AS; Liegl RG; Lackerbauer CA; Eibl KH; Alge CS; Ulbig MW; A AK
    Cornea; 2009 Jun; 28(5):553-61. PubMed ID: 19421040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro safety of intravitreal moxifloxacin for endophthalmitis treatment.
    Kernt M; Neubauer AS; Ulbig MW; Kampik A; Welge-Lüssen U
    J Cataract Refract Surg; 2008 Mar; 34(3):480-8. PubMed ID: 18299076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    Am J Ophthalmol; 2005 Sep; 140(3):497-504. PubMed ID: 16083841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracameral voriconazole: in vitro safety for human ocular cells.
    Kernt M; Kampik A
    Toxicology; 2009 Apr; 258(2-3):84-93. PubMed ID: 19428927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
    Lane SS; Osher RH; Masket S; Belani S
    J Cataract Refract Surg; 2008 Sep; 34(9):1451-9. PubMed ID: 18721703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraocular caspofungin: in vitro safety profile for human ocular cells.
    Kernt M; Kampik A
    Mycoses; 2011 Jul; 54(4):e110-21. PubMed ID: 20202116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients.
    Espiritu CR; Caparas VL; Bolinao JG
    J Cataract Refract Surg; 2007 Jan; 33(1):63-8. PubMed ID: 17189795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model.
    Asena L; Akova YA; Goktaş MT; Bozkurt A; Yaşar U; Karabay G; Demiralay E
    Curr Eye Res; 2013 Apr; 38(4):472-9. PubMed ID: 23373761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of moxifloxacin as shown in animal and in vitro studies.
    McGee DH; Holt WF; Kastner PR; Rice RL
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S46-54. PubMed ID: 16257310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
    Thiele S; Liegl RG; König S; Siedlecki J; Langer J; Eibl K; Haritoglou C; Kampik A; Kernt M
    Klin Monbl Augenheilkd; 2013 Mar; 230(3):247-54. PubMed ID: 23508753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan.
    Matsuura K; Miyoshi T; Suto C; Akura J; Inoue Y
    J Cataract Refract Surg; 2013 Nov; 39(11):1702-6. PubMed ID: 24054967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model.
    Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ
    Am J Ophthalmol; 2004 Jul; 138(1):33-7. PubMed ID: 15234279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracameral Vigamox (moxifloxacin 0.5%) is not effective in preventing endophthalmitis in a rabbit model.
    Kodjikian L; Garweg JG
    Am J Ophthalmol; 2006 Apr; 141(4):777; author reply 777-8. PubMed ID: 16564833
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison between intracameral moxifloxacin administration methods by assessing intraocular concentrations and drug kinetics.
    Matsuura K; Suto C; Akura J; Inoue Y
    Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):1955-9. PubMed ID: 23546399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bag and chamber flushing: a new method of using intracameral moxifloxacin to irrigate the anterior chamber and the area behind the intraocular lens.
    Matsuura K; Suto C; Akura J; Inoue Y
    Graefes Arch Clin Exp Ophthalmol; 2013 Jan; 251(1):81-7. PubMed ID: 22752223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells.
    Kim SY; Park YH; Lee YC
    Clin Exp Ophthalmol; 2008 May; 36(4):367-70. PubMed ID: 18700925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of moxifloxacin and voriconazole in corneal storage media on porcine corneal endothelial cells.
    Kim SY; Yang J; Lee YC
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):315-8. PubMed ID: 20698796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols.
    Herrygers LA; Noecker RJ; Lane LC; Levine JM
    Cornea; 2005 Jan; 24(1):66-71. PubMed ID: 15604869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confocal assessment of the effects of fourth-generation fluoroquinolones on the cornea.
    Ly LT; Cavanagh HD; Petroll WM
    Eye Contact Lens; 2006 Jul; 32(4):161-5. PubMed ID: 16845259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.